



# dottikon

**MEDIA RELEASE**

Dottikon, August 10, 2009

---

## **DOTTIKON ES Strengthens Focus on Processes and Technologies**

Dottikon, Switzerland, August 10, 2009 – The general trend towards shifting development costs to later stages of the clinical development process combined with simultaneous efforts to reduce "time-to-market" and the ongoing consolidation of pharmaceutical pipelines are increasing the complexity and financial risks of process development and exclusive synthesis for pharmaceutical companies. Established experience of scale-ups, rapid adaptability, innovative process technologies, effective project management and reliable quality and delivery are proving to be the key success factors in the customer-specific process development and production of active pharmaceutical ingredients. DOTTIKON ES is gearing itself to these market needs by stepping up technology expansion and strengthening process development and project management.

Dr Max Bachmann will become Head of the newly created "Processes & Technologies" unit on September 1, 2009. As of the same date, Dr Alexander Ernst will become Head of "Marketing & Sales" in addition to his post as Head of "Purchasing".

Both are trained chemists with long recognized track records in active pharmaceutical ingredient and process development as well as exclusive synthesis and production for pharmaceutical companies. They already report direct to CEO Dr Markus Blocher and are members of the Senior Management of the DOTTIKON ES Group.

DOTTIKON ES, with its production site in Dottikon (Aargau, Switzerland), is specialized in hazardous chemical reactions and focuses on the exclusive synthesis of fine chemicals for the pharmaceutical and chemical industry worldwide. The product range of DOTTIKON ES includes active pharmaceutical ingredients (APIs) and pharmaceutical intermediates as well as in-house-developed, high-value industrial chemicals.

DOTTIKON ES HOLDING AG is listed at the SIX Swiss Exchange.

Symbol: DESN

Security number: 2073900

ISIN: CH0020739006

For further information please contact

Dr Markus Blocher  
CEO

Dottikon ES Holding AG  
Tel +41 56 616 82 01  
Fax +41 56 616 89 45  
[investor-relations@dottikon.com](mailto:investor-relations@dottikon.com)

Dottikon ES Holding AG

P.O. Box, 5605 Dottikon, Switzerland, Tel +41 56 616 81 11, Fax +41 56 616 81 20, [info@dottikon.com](mailto:info@dottikon.com), [www.dottikon.com](http://www.dottikon.com)